US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MetaVia Inc

0.7460

-0.0150-1.97%

Volume:49.94K

Turnover:37.64K

Market Cap:7.52M

PE:-0.21

High:0.7667

Open:0.7667

Low:0.7450

Close:0.7610

Loading ...

Overview Company News Filings

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Metavia: No Drug-Induced Cardiovascular Effects Observed in Heart Rate/Qtcf Measurements of Subjects Getting up to 32 Mg of Da-1726 at 4-Weeks

THOMSON REUTERS

Metavia Inc: Additional Cohorts Being Added to Determine Maximum Tolerated Dose

THOMSON REUTERS

Metavia Inc: a Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 Mg and 32 Mg Doses

THOMSON REUTERS

Metavia Inc: Change in Bmi and Body Weight Adjusted for Height in Treatment Groups, Showed a Significant Difference Compared to Placebo

THOMSON REUTERS

Metavia Reports Additional Positive Top-Line Results From the Mad Part 2 of Its Phase 1 Study of Da-1726, a Novel 3:1 Ratio Glp-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-in-Class Potential

THOMSON REUTERS

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

MetaVia Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…

Zacks Small Cap Research

BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, Coty

Metavia Shares up 6.5% After Its Experimental Obesity Drug Shows Promise in Early-Stage Study

THOMSON REUTERS

BUZZ-MetaVia rises after experimental obesity drug shows promise in early-stage study

MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726

Metavia Inc: Additional Cohorts Being Added to Determine Maximum Tolerated Dose

THOMSON REUTERS

Metavia: With No Titration, Demonstrated Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 Mg Dose

THOMSON REUTERS

Metavia Announces Positive Top-Line Data From the 4-Week Phase 1 Mad Trial of Da-1726, a Novel 3:1 Ratio Glp-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-in-Class Glucose Control (Glp-1R), Waist Reduction (Gcgr), and Tolerability

THOMSON REUTERS

Metavia Inc: Study Shows Strong Signal of Glucagon Efficacy at Day 33 at 32 Mg Dos

THOMSON REUTERS

Metavia: Phase 1 Part 3 to Include Wegovy Early Drop-Out Patients to Explore Potential Superiority of Da-1726 on Safety and Tolerability

THOMSON REUTERS

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MTVA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":0.746,"timestamp":1746127568855,"preClose":0.761,"halted":0,"volume":49940,"delay":0,"floatShares":3766600,"shares":10084900,"eps":-3.56,"marketStatus":"Trading","change":-0.015,"latestTime":"05-01 15:48:09 EDT","open":0.7667,"high":0.7667,"low":0.745,"amount":37643.1454542,"amplitude":0.028515,"askPrice":0.7751,"askSize":100,"bidPrice":0.746,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-3.56,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746129600000},"marketStatusCode":2,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":0.761,"preHourTrading":{"tag":"盘前","latestPrice":0.7751,"preClose":0.761,"latestTime":"09:15 EDT","volume":834,"amount":647.36748,"timestamp":1746105314161},"postHourTrading":{"tag":"盘后","latestPrice":0.7505,"preClose":0.761,"latestTime":"19:51 EDT","volume":5702,"amount":4284.079774,"timestamp":1746057081521},"volumeRatio":0.428103},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","floatShares":3766600,"roa":"-92.24%","roe":"-224.18%","lyrEps":-3.556986,"volumeRatio":0.428103,"shares":10084900,"dividePrice":0,"high":0.7667,"amplitude":0.028515,"preClose":0.761,"low":0.745,"week52Low":0.647,"pbRate":"0.95","week52High":5.3,"institutionHeld":0,"latestPrice":0.746,"committee":0.666667,"eps":-3.56,"divideRate":0,"volume":49940,"delay":0,"ttmEps":-3.56,"open":0.7667,"prevYearClose":2.03,"prevWeekClose":0.8226,"prevMonthClose":0.761,"prevQuarterClose":1.54,"fiveDayClose":0.85,"twentyDayClose":1.54,"sixtyDayClose":1.74},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTVA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529500403","title":"MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529500403","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529500403?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:31","pubTimestamp":1745411460,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 23, 2025 /PRNewswire/ --MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis , has been accepted as a late-breaking poster presentation at the European Association for the Study of the Liver  Congress 2025, taking place May 7-10, 2025 in Amsterdam, the Netherlands.Title:DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed Metabolic Dysfunction-Associated Steatohepatitis  Patients. Presenting Author:Rohit Loomba, MD, MHSc, Professor of Medicine in the Division of Gastroenterology, and Adjunct Professor in the Division of Epidemiology at University of California, San Diego.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-announces-breaking-poster-presentation-123100437.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-announces-breaking-poster-presentation-123100437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OXM","BK4139","MTVA","BK4202"],"gpt_icon":0},{"id":"2529301664","title":"BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2529301664","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529301664?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:33","pubTimestamp":1745325188,"startTime":"0","endTime":"0","summary":"BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA6ZJ01N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2529309076","title":"Metavia: No Drug-Induced Cardiovascular Effects Observed in Heart Rate/Qtcf Measurements of Subjects Getting up to 32 Mg of Da-1726 at 4-Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2529309076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529309076?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:31","pubTimestamp":1745325064,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA6ZJ01N:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2529309020","title":"Metavia Inc: Additional Cohorts Being Added to Determine Maximum Tolerated Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2529309020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529309020?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:31","pubTimestamp":1745325064,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA6ZJ01N:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2529309003","title":"Metavia Inc: a Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 Mg and 32 Mg Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2529309003","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529309003?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:31","pubTimestamp":1745325064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA6ZJ01N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2529301880","title":"Metavia Inc: Change in Bmi and Body Weight Adjusted for Height in Treatment Groups, Showed a Significant Difference Compared to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2529301880","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529301880?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:31","pubTimestamp":1745325064,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA6ZJ01N:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2529230907","title":"Metavia Reports Additional Positive Top-Line Results From the Mad Part 2 of Its Phase 1 Study of Da-1726, a Novel 3:1 Ratio Glp-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-in-Class Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2529230907","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529230907?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:31","pubTimestamp":1745325064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA6ZJ01N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2529304614","title":"MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2529304614","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529304614?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:31","pubTimestamp":1745325060,"startTime":"0","endTime":"0","summary":"A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses. Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference Compared to Placebo, Indicating Potentially Greater Efficacy with Increasing Dosage and Longer Duration of Use. No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate or QTcF Measurements of Subjects Receiving up to 32 mg of DA-1726 at 4-Weeks. Additional Cohorts Being Added to Determine Maximum Tolerated Dose. In the 28-day, 36-subject MAD portion of the study, a clear dose-responsive trend in body weight  reduction was observed across the 8 mg to 32 mg range, indicating potentially greater efficacy at higher doses and longer duration of use. Additionally, body mass index , which shows body weight adjusted for height, showed a difference between the treatment group and the placebo  group, which was even more pronounced, further supporting the dose-dependent effect of the drug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-reports-additional-positive-top-123100490.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-reports-additional-positive-top-123100490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MTVA","GLP"],"gpt_icon":0},{"id":"2527021363","title":"MetaVia Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2527021363","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527021363?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:58","pubTimestamp":1744804680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 07:58 ET (11:58 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2527253442","title":"MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…","url":"https://stock-news.laohu8.com/highlight/detail?id=2527253442","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527253442?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:27","pubTimestamp":1744799220,"startTime":"0","endTime":"0","summary":"On April 15, 2025, MetaVia Inc.  announced positive results from the Phase 1 Part 2 multiple ascending dose  trial of DA-1726 in obesity. The results showed that the cohort receiving 32 mg of DA-1726 with no titration had a maximum reduction in body weight from baseline ranging up to -6.3% and a mean body weight reduction of -4.3% . In addition, patients in the 32 mg cohort had a mean waist circumference reduction of 1.6 inches along with a mean reduction in fasting glucose of -5.3 mg/dL. Importantly, gastrointestinal  adverse events  were generally mild and most were only seen after the first dose and resolved within 24 hours of occurrence.The following chart shows the average weight loss on Day 26 for the different dosing cohorts. The 4 mg cohort had an outlier that skewed the overall average weight loss, however the 8 mg, 16 mg, and 32 mg cohorts show a clear dose response.Due to the strong tolerability profile of DA-1726, the company w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mtva-positive-phase-1-mad-102700443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2527425040","title":"BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, Coty","url":"https://stock-news.laohu8.com/highlight/detail?id=2527425040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527425040?lang=en_us&edition=fundamental","pubTime":"2025-04-16 01:53","pubTimestamp":1744739611,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, CotyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv/","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL6N3QT0GU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEDG","BK4108","CHD","VLO","CMPS","FLNC","PNC","RDFN","ACI","LU0788108826.HKD","NKE","CVX","EOSE","ADM","AUR","LU1223082519.USD","MP","SKYE","HRL","LU2249611893.SGD","CYTK","LU1280957306.USD","AMAT","CTVA","LU2468319806.SGD","BK4109","MTVA","LU0795875086.SGD","CAT","IE00B5949003.HKD","NEM","JNJ","ALB","FMC","HWM","HXL","HPE","HUN","COTY","DOW","LVS","XOM","IE00BBT3K403.USD","SPNT","PEP"],"gpt_icon":1},{"id":"2527412684","title":"Metavia Shares up 6.5% After Its Experimental Obesity Drug Shows Promise in Early-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527412684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527412684?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:31","pubTimestamp":1744723915,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0ZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527971134","title":"BUZZ-MetaVia rises after experimental obesity drug shows promise in early-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527971134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527971134?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:47","pubTimestamp":1744717676,"startTime":"0","endTime":"0","summary":"BUZZ-MetaVia rises after experimental obesity drug shows promise in early-stage study** Shares of drug developer MetaVia MTVA.O rise 17.9% to $2.17 premarket** Co says its experimental obesity drug showed a maximum reduction of 6.3% in body weight in a 28-day, 36-patient portion of an early-stage trial** The drug, DA-1726, on average reduced body weight by 4.3% ** Additionally, MTVA says DA-1726 showed waist circumference reduction of 1.6 inches on average, with a maximum reduction of 3.9 inches by day 33     ** \"We anticipate that greater weight loss may be seen in longer duration studies\" - co** In November, co changed its name to MetaVia from NeuroBo Pharmaceuticals** Up to last close, stock had fallen 9.4% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL6N3QT0JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527910184","title":"MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2527910184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527910184?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:05","pubTimestamp":1744715142,"startTime":"0","endTime":"0","summary":"MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual ox...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/metavia-announces-positive-results-from-part-2-of-phase-1-trial-of-da-1726?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/metavia-announces-positive-results-from-part-2-of-phase-1-trial-of-da-1726?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527999814","title":"Metavia Inc: Additional Cohorts Being Added to Determine Maximum Tolerated Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2527999814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527999814?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2527749998","title":"Metavia: With No Titration, Demonstrated Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 Mg Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2527749998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527749998?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527499677","title":"Metavia Announces Positive Top-Line Data From the 4-Week Phase 1 Mad Trial of Da-1726, a Novel 3:1 Ratio Glp-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-in-Class Glucose Control (Glp-1R), Waist Reduction (Gcgr), and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499677?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527499607","title":"Metavia Inc: Study Shows Strong Signal of Glucagon Efficacy at Day 33 at 32 Mg Dos","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499607?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527499153","title":"Metavia: Phase 1 Part 3 to Include Wegovy Early Drop-Out Patients to Explore Potential Superiority of Da-1726 on Safety and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499153","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499153?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2527492780","title":"MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492780","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492780?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714860,"startTime":"0","endTime":"0","summary":"With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% andMean Weight Loss of 4.3% at Day 26 at 32 mg Dose . Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowering of Fasted Glucose of -18 mg/dLand Mean Lowering of -5.3 mg/dL at Day 26 at 32 mg Dose. Maximum Waist Circumference Reduction of3.9 Inches and Mean Reduction of 1.6 InchesDemonstrates Strong Signal ofGlucagon Efficacy at Day 33 at 32 mg Dose. Additional Cohorts Being Added to Determine Maximum Tolerated Dose. Planned Phase 1 Part 3 to Include Wegovy Early Drop-Out Patients to Explore Potential Superiority of DA-1726 on Safety and Tolerability, Along With Weight Loss and Other Secondary Endpoints. CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ -- MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose  Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin  an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-110100485.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-110100485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","BK4590","BK4157","BMI","GLP","BK4202","LU1169589451.USD","PK","BK4218","BK4144","MTVA","BK4181","PD","OXM","BK4139","LU1169590202.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTVA\",params:#limit:5,,,undefined,":[{"date":"2025-03-20","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742457600000,"name":null,"time":"Pre-Market","dateTimestamp":1742443200000,"actualEps":null},{"market":"US","date":"2024-11-07","symbol":"MTVA","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.55},{"market":"US","date":"2024-08-14","symbol":"MTVA","fiscalQuarterEnding":"2024/06","expectedEps":-1.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":-1.85},{"market":"US","date":"2024-05-09","symbol":"MTVA","fiscalQuarterEnding":"2024/03","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-1.32},{"date":"2024-03-28","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711612800000,"name":null,"time":"Pre-Market","dateTimestamp":1711598400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTVA","date":"2025-04-29","current":-0.248115,"percent":0.96,"low":-0.807761,"twenty":-0.630675,"median":-0.512617,"eighty":-0.459802,"high":-0.229797,"avg":-0.531767,"sd":0.129149,"marketCap":6846001},"quantilePoints":[{"date":"2024-12-06","current":-0.714557,"twenty":-0.800304,"median":-0.792227,"eighty":-0.751814,"marketCap":19816823},{"date":"2024-12-13","current":-0.716111,"twenty":-0.79347,"median":-0.728538,"eighty":-0.7158,"marketCap":19859903},{"date":"2024-12-20","current":-0.546792,"twenty":-0.767348,"median":-0.716111,"eighty":-0.685354,"marketCap":15164177},{"date":"2024-12-27","current":-0.562326,"twenty":-0.746234,"median":-0.70213,"eighty":-0.556112,"marketCap":15594978},{"date":"2025-01-03","current":-0.655529,"twenty":-0.730091,"median":-0.686597,"eighty":-0.553006,"marketCap":18179781},{"date":"2025-01-10","current":-0.661742,"twenty":-0.733198,"median":-0.686597,"eighty":-0.564811,"marketCap":18352101},{"date":"2025-01-17","current":-0.58718,"twenty":-0.720771,"median":-0.663296,"eighty":-0.577238,"marketCap":16284258},{"date":"2025-01-24","current":-0.602714,"twenty":-0.720771,"median":-0.647762,"eighty":-0.584073,"marketCap":16715059},{"date":"2025-01-31","current":-0.584073,"twenty":-0.717664,"median":-0.630675,"eighty":-0.584073,"marketCap":16198098},{"date":"2025-02-07","current":-0.562326,"twenty":-0.716111,"median":-0.615141,"eighty":-0.562326,"marketCap":15594978},{"date":"2025-02-14","current":-0.512617,"twenty":-0.714557,"median":-0.608927,"eighty":-0.546792,"marketCap":14216416},{"date":"2025-02-21","current":-0.509511,"twenty":-0.704615,"median":-0.602714,"eighty":-0.540578,"marketCap":14130256},{"date":"2025-02-28","current":-0.453589,"twenty":-0.699297,"median":-0.58718,"eighty":-0.518583,"marketCap":12579374},{"date":"2025-03-07","current":-0.487763,"twenty":-0.688995,"median":-0.584073,"eighty":-0.503297,"marketCap":13527135},{"date":"2025-03-14","current":-0.467569,"twenty":-0.681626,"median":-0.568539,"eighty":-0.495468,"marketCap":12967095},{"date":"2025-03-21","current":-0.48401,"twenty":-0.667956,"median":-0.562326,"eighty":-0.487763,"marketCap":13354815},{"date":"2025-03-28","current":-0.48933,"twenty":-0.662363,"median":-0.546792,"eighty":-0.487763,"marketCap":13501595},{"date":"2025-04-04","current":-0.47992,"twenty":-0.656772,"median":-0.540578,"eighty":-0.485083,"marketCap":13241949},{"date":"2025-04-11","current":-0.429732,"twenty":-0.643102,"median":-0.539025,"eighty":-0.482756,"marketCap":11857170},{"date":"2025-04-17","current":-0.23033,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"marketCap":6355270},{"date":"2025-04-25","current":-0.266622,"twenty":-0.631917,"median":-0.512617,"eighty":-0.463425,"marketCap":7356638},{"date":"2025-04-29","current":-0.248115,"twenty":-0.630675,"median":-0.512617,"eighty":-0.459802,"marketCap":6846001}],"updateTime":1746086298552}}}